Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Fludeoxyglucose F-18

Review the clinical trials studying fludeoxyglucose f-18 on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 81

Testing the Use of Combination Therapy in Adult Patients with Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Status: Active
Location: 595 locations
Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Status: Active
Location: 693 locations
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Status: Active
Location: 355 locations
Testing Continuous versus Intermittent Treatment with the Study Drug Zanubrutinib for Older Patients with Previously Untreated Mantle Cell Lymphoma
Status: Active
Location: 225 locations
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Status: Active
Location: 179 locations
Comparing Sentinel Lymph Node (SLN) Biopsy with Standard Neck Dissection for Patients with Early-Stage Oral Cavity Cancer
Status: Active
Location: 92 locations
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients with Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
Status: Active
Location: 32 locations
Testing Lutetium Lu 177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Status: Active
Location: 28 locations
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
Status: Active
Location: 13 locations
Epcoritamab for the Treatment of Newly Diagnosed Marginal Zone Lymphoma
Status: Active
Location: 8 locations
A Study of Talquetamab for Treating Patients with Relapsed or Refractory Multiple Myeloma who have Received BCMA CAR T-Cell Therapy
Status: Active
Location: 7 locations
A Study of Tucatinib and Trastuzumab in Patients with HER2-Positive Locally Advanced Rectal Cancer
Status: Active
Location: 7 locations
Glofitamab-based Treatment in Older Adults with Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma or Transformed Lymphoma, GLORY Trial
Status: Active
Location: 7 locations
Alectinib in Combination with Duvelisib for the Treatment of Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma
Status: Active
Location: 7 locations
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma
Status: Active
Location: 7 locations
Teclistamab or Talquetamab in Combination with Daratumumab for the Treatment of High-Risk Smoldering Multiple Myeloma, The REVIVE Trial
Status: Active
Location: 6 locations
Atezolizumab in Combination with Chemotherapy in Treating Pediatric Patients with Relapsed or Refractory Solid Tumors, VITAS Trial
Status: Active
Location: 7 locations
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Location: 3 locations
Nivolumab in Combination with Axitinib for the Treatment of Advanced or Unresectable Mucosal Melanoma
Status: Active
Location: 2 locations
Autologous hALK. Chimeric Antigen Receptor T Cells (hALK.CAR T) for the Treatment of Relapsed or Refractory High-Risk Neuroblastoma
Status: Active
Location: 2 locations
Atezolizumab with Stereotactic Body Radiation Therapy and Surgery for the Treatment of Patients with Osteosarcoma with Pulmonary Metastasis
Status: Active
Location: 2 locations
18F-Fluciclovine PET/CT in Multiple Myeloma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Chest Radiation Therapy to Prevent Progression of Symptoms in Stage IV Non-small Cell Lung Cancer
Status: Active
Location: University of Rochester, Rochester, New York
Tazemetostat for the Treatment of Patients with Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors
Status: Active
Location: University of Florida Health Science Center - Gainesville, Gainesville, Florida
Radiotherapy Dose De-escalation for the Treatment of HPV-Associated Cancers of the Oropharynx
Status: Active
Location: Duke University Medical Center, Durham, North Carolina